GSK1838705A (GSK-1838705A) is a novel, potent and reversible small-molecule IGF-1R inhibitor with potential anticancer activity.

Ensartinib (formerly known as X-396) is a novel, highly potent and selective, orally available small molecule inhibitor of ALK (anaplastic lymphoma kinase) with an IC50 less than 4 nM in Ambit assays.

Ceritinib (formerly known as LDK378; trade name: Zykadia) is novel, potent and selective inhibitor against ALK (anaplastic lymphoma kinase positive) with potential anticancer activity.

TPX 0131 (TPX-0131) is a novel, potent CNS-penetrant ALK inhibitor with anticancer activity.

X-376 (an analog of Ensartinib or X-396) is a novel, potent and highly selective ALK inhibitor with IC50 of 0.61 nM and the potential to be used for treating non-small cell lung cancer.